Isami Kuruma
About
In The Last Decade
Isami Kuruma
41 papers receiving 482 citations
Peers
Comparison fields: 5 of 86
- Cellular and Molecular Neuroscience 183
- Molecular Biology 138
- Neurology 117
- Pharmacology 67
- Physiology 59
Countries citing papers authored by Isami Kuruma
This map shows the geographic impact of Isami Kuruma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isami Kuruma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isami Kuruma more than expected).
Fields of papers citing papers by Isami Kuruma
This network shows the impact of papers produced by Isami Kuruma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isami Kuruma. The network helps show where Isami Kuruma may publish in the future.
Co-authorship network of co-authors of Isami Kuruma
This figure shows the co-authorship network connecting the top 25 collaborators of Isami Kuruma. A scholar is included among the top collaborators of Isami Kuruma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isami Kuruma. Isami Kuruma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 10 | |
| 2 | 3 | |
| 3 | 9 | |
| 4 | 3 | |
| 5 | 3 | |
| 6 | 6 | |
| 7 | 13 | |
| 8 | 9 | |
| 9 | METABOLIC FATE OF TENOXICAM AND A POSSIBLE MECHANISM OF ANTI-INFLAMMATORY ACTIVITY | 2 |
| 10 | 1 | |
| 11 | 48 | |
| 12 | 2 | |
| 13 | 1 | |
| 14 | [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)]. | 4 |
| 15 | 7 | |
| 16 | 24 | |
| 17 | 5 | |
| 18 | 1 | |
| 19 | 4 | |
| 20 | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.